MY CHART NEVER LIES
During the pandemic, orthodontic services have been restricted. ALGN allows patients a safe, lower-cost way, to achieve their goal for a better dental appearance. Patients work with orthodontists, but wear an aligner for their teeth that is not visible to others. Management just amped up their sales expectations to $3.7-$3.9 billion for the year, compared to analyst expectations of $3.49 billion. The company is expanding to include Europe, Japan, and China. The company continues to build cash reserves, now estimated at over $1.2 billion. We would buy this with a stop loss at $400, looking to achieve $707 -- upside potential over 25%. Yield 0% (Analysts’ price target is $707.00)
During the pandemic, orthodontic services have been restricted. ALGN allows patients a safe, lower-cost way, to achieve their goal for a better dental appearance. Patients work with orthodontists, but wear an aligner for their teeth that is not visible to others. Management just amped up their sales expectations to $3.7-$3.9 billion for the year, compared to analyst expectations of $3.49 billion. The company is expanding to include Europe, Japan, and China. The company continues to build cash reserves, now estimated at over $1.2 billion. We would buy this with a stop loss at $400, looking to achieve $707 -- upside potential over 25%. Yield 0% (Analysts’ price target is $707.00)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.